Second Diamyd type 1 diabetes prevention trial started

Today the second Diamyd (GAD65) prevention trial was approved by the Swedish medical authorities.

It will be conducted at Lund University hospital in Sweden.
The trial will include 50 children from 4 years of age, randomized and placebo controlled.

The fact that children as young as 4 years old where approved for this trial is good evidence on the amazing safety profile Diamyd (GAD65) has shown so far.

"To stop the immune attack on the insulin producing cells in type 1 diabetes may be easier the sooner it is done in the disease process", says Professor Åke Lernmark, at Lund University, Sweden. "It is like steering a big boat away from a threatening collision. The sooner the course is changed, the better. A timely change in the course of the disease - no insulin injections - that may be this century's contribution to curing autoimmune diabetes. Last century's contribution? Insulin injections!"

Now we are only waiting for Trialnet to also start the US prevention trial, using identified high-risk patients identified in the Natural History Study.

Source:
Diamyd Press release